Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A global effort to dissect the human genetic basis of resistance to SARS-CoV-2 infection

  • Andreakos, Evangelos
  • Abel, Laurent
  • Vinh, Donald C.
  • Kaja, Elżbieta
  • Drolet, Beth A.
  • Zhang, Qian
  • O’Farrelly, Cliona
  • Novelli, Giuseppe
  • Rodríguez-Gallego, Carlos
  • Haerynck, Filomeen
  • Prando, Carolina
  • Pujol, Aurora
  • COVID Human Genetic Effort
  • Su, Helen C.
  • Casanova, Jean-Laurent
  • Spaan, András N.
SARS-CoV-2 infections display tremendous interindividual variability, ranging from asymptomatic infections to life-threatening disease. Inborn errors of, and autoantibodies directed against, type I interferons (IFNs) account for about 20% of critical COVID-19 cases among SARS-CoV-2-infected individuals. By contrast, the genetic and immunological determinants of resistance to infection per se remain unknown. Following the discovery that autosomal recessive deficiency in the DARC chemokine receptor confers resistance to Plasmodium vivax, autosomal recessive deficiencies of chemokine receptor 5 (CCR5) and the enzyme FUT2 were shown to underlie resistance to HIV-1 and noroviruses, respectively. Along the same lines, we propose a strategy for identifying, recruiting, and genetically analyzing individuals who are naturally resistant to SARS-CoV-2 infection., The Laboratory of Human Genetics of Infectious Diseases is supported by the National Institutes of Health (NIH) (R01AI088364), the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program (UL1TR001866), a Fast Grant from Emergent Ventures, Mercatus Center at George Mason University, the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956), the Fisher Center for Alzheimer’s Research Foundation, the Meyer Foundation, the French National Research Agency (ANR) under the Investments for the Future program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (EQU201903007798), the FRM and ANR GENCOVID project (ANR-20-COVI-0003), ANRS-COV05, the Fondation du Souffle, the Square Foundation, Grandir - Fonds de solidarité pour l’enfance, the SCOR Corporate Foundation for Science, the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, Institut National de la Santé et de la Recherche Médicale (INSERM), and the University of Paris. E.A. is supported by research grants from the European Commission’s Horizon 2020 research and innovation program (IMMUNAID, grant no. 779295, CURE, grant no. 767015 and TO_AITION grant no. 848146) and the Hellenic Foundation for Research and Innovation (INTERFLU, no. 1574). C.O.F. is supported in part by the Science Foundation Ireland COVID-19 Program. G.N. is supported by a grant awarded to Regione Lazio (Research Group Projects 2020) no. A0375-2020-36663, GecoBiomark. A.P. is supported in part by the Horizon 2020 program under grant no. 824110 (EasiGenomics grant no. COVID-19/PID12342) and the CERCA Program/Generalitat de Catalunya. H.S. is supported in part by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. A.S. is supported in part by the European Union’s Horizon 2020 research and innovation program (Marie Sklodowska-Curie grant no. 789645).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs

  • Bastard, Paul
  • Vazquez, Sara E.
  • Liu, Jamin
  • Laurie, Matthew T.
  • Wang, Chung Yu
  • Gervais, Adrian
  • Le Voyer, Tom
  • Bizien, Lucy
  • Zamecnik, Colin
  • Philippot, Quentin
  • Rosain, Jérémie
  • Allende, Luis M.
  • Martinez-Picado, Javier
  • Ozcelik, Tayfun
  • Imberti, Luisa
  • Notarangelo, Luigi D.
  • Troya, Jesus
  • Solanich, Xavier
  • Zhang, Shen-Ying
  • Puel, Anne
  • Wilson, Michael R.
  • Trouillet-Assant, Sophie
  • Abel, Laurent
  • Jouanguy, Emmanuelle
  • Ye, Chun Jimmie
  • Cobat, Aurélie
  • Thompson, Leslie M.
  • Andreakos, Evangelos
  • Zhang, Qian
  • Anderson, Mark S.
  • Casanova, Jean-Laurent
  • DeRisi, Joseph L.
  • Catherinot, Emilie
  • Willmore, Andrew
  • Mitchell, Anthea M.
  • Bair, Rebecca
  • Garçon, Pierre
  • Kenney, Heather
  • Fekkar, Arnaud
  • Salagianni, Maria
  • Poulakou, Garyphallia
  • Siouti, Eleni
  • Sahanic, Sabina
  • Tancevski, Ivan
  • Weiss, Günter
  • Nagl, Laurenz
  • Manry, Jérémy
  • Duvlis, Sotirija
  • Arroyo-Sánchez, Daniel
  • Paz Artal, Estela
  • Rubio, Luis
  • Perani, Cristiano
  • Bezzi, Michela
  • Sottini, Alessandra
  • Quaresima, Virginia
  • Roussel, Lucie
  • Vinh, Donald C.
  • Reyes, Luis Felipe
  • Garzaro, Margaux
  • Hatipoglu, Nevin
  • Boutboul, David
  • Tandjaoui-Lambiotte, Yacine
  • Borghesi, Alessandro
  • Aliberti, Anna
  • Cassaniti, Irene
  • Venet, Fabienne
  • Monneret, Guillaume
  • Halwani, Rabih
  • Sharif-Askari, Narjes Saheb
  • Danielson, Jeffrey
  • Burrel, Sonia
  • Morbieu, Caroline
  • Stepanovskyy, Yurii
  • Bondarenko, Anastasia
  • Volokha, Alla
  • Boyarchuk, Oksana
  • Gagro, Alenka
  • Neuville, Mathilde
  • Neven, Bénédicte
  • Keles, Sevgi
  • Hernu, Romain
  • Bal, Antonin
  • Novelli, Antonio
  • Novelli, Giuseppe
  • Saker, Kahina
  • Ailioaie, Oana
  • Antolí, Arnau
  • Jeziorski, Eric
  • Rocamora-Blanch, Gemma
  • Teixeira, Carla
  • Delaunay, Clarisse
  • Lhuillier, Marine
  • Le Turnier, Paul
  • Zhang, Yu
  • Mahevas, Matthieu
  • Pan-Hammarström, Qiang
  • Abolhassani, Hassan
  • Bompoil, Thierry
  • Dorgham, Karim
  • Gorochov, Guy
  • Laouenan, Cédric
  • Rodríguez-Gallego, Carlos
  • Ng, Lisa F. P.
  • Renia, Laurent
  • Pujol, Aurora
  • Belot, Alexandre
  • Raffi, François
Life-threatening "breakthrough" cases of critical COVID-19 are attributed to poor or waning antibody (Ab) response to SARS-CoV-2 vaccines in individuals already at risk. Preexisting auto-Abs neutralizing type I IFNs underlie at least 15% of critical COVID-19 pneumonia cases in unvaccinated individuals; their contribution to hypoxemic breakthrough cases in vaccinated people is unknown. We studied a cohort of 48 individuals (aged 20 to 86 years) who received two doses of a messenger RNA (mRNA) vaccine and developed a breakthrough infection with hypoxemic COVID-19 pneumonia 2 weeks to 4 months later. Ab levels to the vaccine, neutralization of the virus, and auto-Abs to type I IFNs were measured in the plasma. Forty-two individuals had no known deficiency of B cell immunity and a normal Ab response to the vaccine. Among them, 10 (24%) had auto-Abs neutralizing type I IFNs (aged 43 to 86 years). Eight of these 10 patients had auto-Abs neutralizing both IFN-α2 and IFN-ω, whereas two neutralized IFN-ω only. No patient neutralized IFN-β. Seven neutralized type I IFNs at 10 ng/ml and three at 100 pg/ml only. Seven patients neutralized SARS-CoV-2 D614G and Delta efficiently, whereas one patient neutralized Delta slightly less efficiently. Two of the three patients neutralizing only type I IFNs at 100 pg/ml neutralized both D614G and Delta less efficiently. Despite two mRNA vaccine inoculations and the presence of circulating Abs capable of neutralizing SARS-CoV-2, auto-Abs neutralizing type I IFNs may underlie a notable proportion of hypoxemic COVID-19 pneumonia cases, highlighting the importance of this particularly vulnerable population., The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute; The Rockefeller University; the St. Giles Foundation; the NIH (R01AI088364 and R01AI163029); the National Center for Advancing Translational Sciences (NCATS); NIH Clinical and Translational Science Award (CTSA) program (UL1 TR001866); a Fast Grant from Emergent Ventures, Mercatus Center at George Mason University; the Fisher Center for Alzheimer’s Research Foundation; the Meyer Foundation; the JPB Foundation; the program “Investissement d’Avenir” launched by the French Government and implemented by the Agence Nationale de la Recherche (ANR) with references ANR-21-RHUS-08 and ANR-10-IAHU-01; the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID); the French Foundation for Medical Research (FRM; EQU201903007798); the ANRS-COV05, ANR GENVIR (ANR-20-CE93-003), ANR AABIFNCOV (ANR-20-CO11-0001), and ANR GenMISC (ANR-21-COVR-0039) projects; the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 824110 (EASI-genomics); the Square Foundation; Grandir–Fonds de solidarité pour l’enfance; the Fondation du Souffle; the SCOR Corporate Foundation for Science; the French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19); Institut National de la Santé et de la Recherche Médicale (INSERM); REACTing-INSERM; and the University of Paris. C.R.-G., R.P.D., and C.F. were funded by Instituto de Salud Carlos III (COV20_01333 and COV20_01334), the Spanish Ministry of Science and Innovation (RTC-2017-6471-1; AEI/FEDER, UE), the Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC19/43California grant no. 779295). L.R. and L.F.P.N. were supported by Singapore National Medical Research Council COVID-19 Research Fund (COVID19RF-001, COVID19RF-007, COVID19RF-0008, and COVID19RF-060) and A*STAR COVID-19 Research funding (H/20/04/g1/006). The UCSF COMET Consortium is supported by the Clinical and Translational Science Institute University of California, San Francisco and the NIH (U19AI077439). A.A., G.R.-B., and X.S. are funded by the 202115-31 project, funded by La Marató de TV3. L.D.N. was supported by the intramural Research Program of the NIAID, NIH. J.L.D. is supported by the Chan Zuckerberg Biohub. We acknowledge the support of the Chao Family Comprehensive Cancer Center Experimental Tissue Shared Resource, supported by the National Cancer Institute of the NIH under award number P30CA062203. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. P.B. was supported by the FRM (EA20170638020). P.B. and T.L.V. were supported by the MD-PhD program of the Imagine Institute (with the support of the Fondation Bettencourt-Schueller)., Peer reviewed